Christopher Pittman: How Pre-Op Vein Treatment Can Lower VTE Risk in Orthopedic Surgery
Haroun Gajraj, Phlebologist and Board Member of the British Association of Sclerotherapists, reposted Christopher Pittman’s post on LinkedIn:
“This adds to previous studies confirming that Superficial Venous Disease is a risk factor for DVT and PE that can be MODIFIED…
Thank you Christopher Pittman for bringing this to our attention and for your analysis of the impact of this new research.”
Quoting Christopher Pittman’s post:
“Postoperative VTE Risk and the Overlooked Role of Venous Insufficiency: Orthopedic + Vein crossover alert
Recent matched cohort analysis in the Journal of Orthopaedics, 2025 using the PearlDiver database (n > 23,000 TKA patients) showed:
- Significant reduction in VTE events in patients who had preoperative treatment of varicose veins
- Patients with untreated lower extremity venous insufficiency had notably higher rates of DVT/PE post–total knee arthroplasty
- Adjusted analysis confirmed lower odds of thromboembolic events when venous disease was managed prior to surgery
Clinical implication:
Venous insufficiency isn’t just cosmetic—it may be a modifiable surgical risk factor. Pre-op screening and referral to a vein specialist could reduce morbidity in high-risk orthopedic patients.
If you’re operating on knees, hips, or ankles—especially in patients >50 with visible varicosities or edema—it may be time to rethink your VTE prevention strategy.
Let’s bridge the gap between phlebology and orthopedics. The data is compelling.”
Title: Does Surgical Treatment of Varicose Veins Prior to Total Knee Arthroplasty Decrease Rates of Postoperative Venous Thromboembolism? A Matched Cohort Study
Authors: Mary Jane McConnell, Bailey J. Ross, Jordan Murphy, George N. Guild Ⅲ, Brandon H. Naylor, Thomas L. Bradbury

Read the full article here.
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC